68Ga-PSMA PET in the Prostate Cancer

Launched by XIJING HOSPITAL · Jul 11, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging test called 68Ga-PSMA PET/CT to see how well it can detect cancer spread to the lymph nodes in men who have been newly diagnosed with prostate cancer. The goal is to compare this imaging method with another test called mpMRI to find out which one is better at spotting cancer in these lymph nodes. The trial is currently looking for male participants who are at high risk of having localized or locally advanced prostate cancer and are planning to undergo surgery to remove the prostate and nearby lymph nodes.

To be eligible for the study, participants need to have a specific type of prostate cancer with a Gleason grade of 4 or higher, which indicates a more aggressive cancer. However, if someone has had another type of cancer in the last five years (except for certain skin cancers) or has certain medical conditions that could affect their ability to participate, they may not be able to join. Participants can expect to undergo both imaging tests during the trial, and the results will help doctors understand which method is more effective for diagnosing cancer spread in the lymph nodes.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • High risk localized/locally advanced prostate cancer patients who are candidates for radical prostatectomy plus bilateral extended PLND
• • ISUP Gleason grade group ≥ 4
• Exclusion Criteria:
• • Prior history of any other cancer in the last 5 years excluding basal cell carcinoma Proven metastases in bones or other distant metastases
• • General contra-indications for MRI (pacemaker, aneurysm clips, any form of metal in the body, severe claustrophobia)
• • Serious concomitant systemic disorders that in the opinion of the investigator would compromise the patient's ability to complete the study or interfere with the evaluation of the efficacy and safety of the study objectives
• • Metal implants in the pelvic region which will deteriorate PET/MR/CT image quality.